Contract development and manufacturing organisation (CDMO) SCTbio and cell therapy company Cyto-care.eu have teamed up with the aim of improving the quality of cryopreservation in Europe.
The goal of the collaboration is to address the critical need for efficient collection, cryopreservation, quality control and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.
Cell collection through leukapheresis procedure is a key enabling step for manufacturing advanced cell therapies products (ATMPs), cutting-edge medicines made from human cells or tissue that are today life-saving therapies.
ATMPThe quantity and quality of collected immune cells, like T cells and natural killer cells used for cell therapies, directly impact the potency, safety and efficacy of the final therapeutic product.
As such, efficient cryopreservation and logistics of these leukapheresis materials are critical to ensure the preservation of cell viability and functionality during transportation and storage.
Together, Cyto-care.eu and SCTbio hope to provide a reliable and accessible platform for collecting, characterising, preserving, and transporting leukapheresis samples.
Luděk Sojka, CEO of SCTbio, commented: “As the cell and gene therapy field continues to advance, the demand for leukapheresis materials is expected to increase. Clinical trials and commercial production of these therapies require a consistent and reliable supply of high-quality blood-derived products to meet patient needs.”
